Virtus LifeSci Biotech Clinical Trials ETF
18 hedge funds and large institutions have $39.5M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
21.28% more ownership
Funds ownership: 29.29% → 50.58% (+21%)
Holders
18
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$16.7M | |
| 2 | +$7.47M | |
| 3 | +$1.97M | |
| 4 |
WKWM
Walter & Keenan Wealth Management
Souh Bend,
Indiana
|
+$1.83M |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$702K |
Top Sellers
| 1 | -$455K | |
| 2 | -$74K | |
| 3 | -$61.9K | |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$14.4K |